Guangzhou High-tech Zone gives Akeso Pharmaceuticals a financial boost

Akeso Pharmaceuticals, a subsidiary of Akesobio, and Guangzhou High-tech Investment Group held a strategic cooperation signing ceremony on Nov 15. The group will provide 500 million yuan ($70 million) of financial support to the joint venture. 

Akeso Pharmaceuticals is a key enterprise in Guangzhou, mainly responsible for the clinical development, industrialization, and commercialization of Cadonilimab, a new antibody drug that was independently developed by Akesobio. 

Approved for marketing in June 2022, Cadonilimab is the world's first dual immune checkpoint bispecific antibody that deals with a range of tumors, and the first independently developed bispecific antibody medicine approved in China.

Akesobio's R&D and production base are located in China-Singapore Guangzhou Knowledge City (CSGKC).

Share - WeChat